747 related articles for article (PubMed ID: 33730088)
1. COVID-19 Evidence Accelerator: A parallel analysis to describe the use of Hydroxychloroquine with or without Azithromycin among hospitalized COVID-19 patients.
Stewart M; Rodriguez-Watson C; Albayrak A; Asubonteng J; Belli A; Brown T; Cho K; Das R; Eldridge E; Gatto N; Gelman A; Gerlovin H; Goldberg SL; Hansen E; Hirsch J; Ho YL; Ip A; Izano M; Jones J; Justice AC; Klesh R; Kuranz S; Lam C; Mao Q; Mataraso S; Mera R; Posner DC; Rassen JA; Siefkas A; Schrag A; Tourassi G; Weckstein A; Wolf F; Bhat A; Winckler S; Sigal EV; Allen J
PLoS One; 2021; 16(3):e0248128. PubMed ID: 33730088
[TBL] [Abstract][Full Text] [Related]
2. Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State.
Rosenberg ES; Dufort EM; Udo T; Wilberschied LA; Kumar J; Tesoriero J; Weinberg P; Kirkwood J; Muse A; DeHovitz J; Blog DS; Hutton B; Holtgrave DR; Zucker HA
JAMA; 2020 Jun; 323(24):2493-2502. PubMed ID: 32392282
[TBL] [Abstract][Full Text] [Related]
3. Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19.
Arshad S; Kilgore P; Chaudhry ZS; Jacobsen G; Wang DD; Huitsing K; Brar I; Alangaden GJ; Ramesh MS; McKinnon JE; O'Neill W; Zervos M;
Int J Infect Dis; 2020 Aug; 97():396-403. PubMed ID: 32623082
[TBL] [Abstract][Full Text] [Related]
4. Pharmacoepidemiology, Machine Learning, and COVID-19: An Intent-to-Treat Analysis of Hydroxychloroquine, With or Without Azithromycin, and COVID-19 Outcomes Among Hospitalized US Veterans.
Gerlovin H; Posner DC; Ho YL; Rentsch CT; Tate JP; King JT; Kurgansky KE; Danciu I; Costa L; Linares FA; Goethert ID; Jacobson DA; Freiberg MS; Begoli E; Muralidhar S; Ramoni RB; Tourassi G; Gaziano JM; Justice AC; Gagnon DR; Cho K
Am J Epidemiol; 2021 Nov; 190(11):2405-2419. PubMed ID: 34165150
[TBL] [Abstract][Full Text] [Related]
5. Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis.
Fiolet T; Guihur A; Rebeaud ME; Mulot M; Peiffer-Smadja N; Mahamat-Saleh Y
Clin Microbiol Infect; 2021 Jan; 27(1):19-27. PubMed ID: 32860962
[TBL] [Abstract][Full Text] [Related]
6. Zinc sulfate in combination with a zinc ionophore may improve outcomes in hospitalized COVID-19 patients.
Carlucci PM; Ahuja T; Petrilli C; Rajagopalan H; Jones S; Rahimian J
J Med Microbiol; 2020 Oct; 69(10):1228-1234. PubMed ID: 32930657
[No Abstract] [Full Text] [Related]
7. Hydroxychloroquine and tocilizumab therapy in COVID-19 patients-An observational study.
Ip A; Berry DA; Hansen E; Goy AH; Pecora AL; Sinclaire BA; Bednarz U; Marafelias M; Berry SM; Berry NS; Mathura S; Sawczuk IS; Biran N; Go RC; Sperber S; Piwoz JA; Balani B; Cicogna C; Sebti R; Zuckerman J; Rose KM; Tank L; Jacobs LG; Korcak J; Timmapuri SL; Underwood JP; Sugalski G; Barsky C; Varga DW; Asif A; Landolfi JC; Goldberg SL
PLoS One; 2020; 15(8):e0237693. PubMed ID: 32790733
[TBL] [Abstract][Full Text] [Related]
8. Triple therapy with hydroxychloroquine, azithromycin, and ciclesonide for COVID-19 pneumonia.
Mori N; Katayama M; Nukaga S
J Microbiol Immunol Infect; 2021 Feb; 54(1):109-112. PubMed ID: 33054978
[TBL] [Abstract][Full Text] [Related]
9. Effect of hydroxychloroquine with or without azithromycin on the mortality of COVID-19 patients: authors' response.
Fiolet T; Guihur A; Rebeaud ME; Mulot M; Peiffer-Smadja N; Mahamat-Saleh Y
Clin Microbiol Infect; 2021 Jan; 27(1):138-140. PubMed ID: 33080383
[No Abstract] [Full Text] [Related]
10. Prescribing practices of lopinavir/ritonavir, hydroxychloroquine and azithromycin during the COVID-19 epidemic crisis and pharmaceutical interventions in a French teaching hospital.
Gourieux B; Reisz F; Belmas AS; Danion F; Fourtage M; Nai T; Reiter-Schatz A; Ruch Y; Walther J; Nivoix Y; Michel B
Eur J Hosp Pharm; 2021 Sep; 28(5):242-247. PubMed ID: 33239282
[TBL] [Abstract][Full Text] [Related]
11. Hydroxychloroquine use in hospitalised patients with COVID-19: An observational matched cohort study.
Kalligeros M; Shehadeh F; Atalla E; Mylona EK; Aung S; Pandita A; Larkin J; Sanchez M; Touzard-Romo F; Brotherton A; Shah R; Cunha CB; Mylonakis E
J Glob Antimicrob Resist; 2020 Sep; 22():842-844. PubMed ID: 32763357
[TBL] [Abstract][Full Text] [Related]
12. Outcome of noncritical COVID-19 patients with early hospitalization and early antiviral treatment outside the ICU.
Çalık Başaran N; Uyaroğlu OA; Telli Dizman G; Özışık L; Şahin TK; Taş Z; İnkaya AÇ; Karahan S; Alp Ş; Alp A; Metan G; Zarakol P; Sain Güven G; Öz ŞG; Topeli A; Uzun Ö; Akova M; Ünal S
Turk J Med Sci; 2021 Apr; 51(2):411-420. PubMed ID: 32718127
[TBL] [Abstract][Full Text] [Related]
13. Hydroxychloroquine plus azithromycin and early hospital admission are beneficial in COVID-19 patients: Turkish experience with real-life data.
Tanriverdİ E; Çörtük M; Yildirim BZ; Uğur Chousein EG; Turan D; Çinarka H; Özgül MA; Çetinkaya E
Turk J Med Sci; 2021 Feb; 51(1):10-5. PubMed ID: 32682360
[TBL] [Abstract][Full Text] [Related]
14. Proactive prophylaxis with azithromycin and hydroxychloroquine in hospitalized patients with COVID-19 (ProPAC-COVID): a statistical analysis plan.
Sivapalan P; Ulrik CS; Lappere TS; Eklöf JV; Shaker SB; Bødtger UCS; Browatzki A; Meyer CN; Weinreich UM; Laursen CB; Biering-Sørensen T; Knop FK; Lundgren JD; Jensen JS
Trials; 2020 Oct; 21(1):867. PubMed ID: 33081817
[TBL] [Abstract][Full Text] [Related]
15. Effect of hydroxychloroquine and azithromycin on the viral clearance of SARS-CoV-2: response to Hervé Seligmann.
Gautret P; Hoang VT; Colson P; Raoult D
Int J Antimicrob Agents; 2021 Mar; 57(3):106306. PubMed ID: 33596459
[No Abstract] [Full Text] [Related]
16. Combination of Hydroxychloroquine Plus Azithromycin As Potential Treatment for COVID-19 Patients: Safety Profile, Drug Interactions, and Management of Toxicity.
Hache G; Rolain JM; Gautret P; Deharo JC; Brouqui P; Raoult D; Honoré S
Microb Drug Resist; 2021 Mar; 27(3):281-290. PubMed ID: 33729874
[TBL] [Abstract][Full Text] [Related]
17. Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial.
Furtado RHM; Berwanger O; Fonseca HA; Corrêa TD; Ferraz LR; Lapa MG; Zampieri FG; Veiga VC; Azevedo LCP; Rosa RG; Lopes RD; Avezum A; Manoel ALO; Piza FMT; Martins PA; Lisboa TC; Pereira AJ; Olivato GB; Dantas VCS; Milan EP; Gebara OCE; Amazonas RB; Oliveira MB; Soares RVP; Moia DDF; Piano LPA; Castilho K; Momesso RGRAP; Schettino GPP; Rizzo LV; Neto AS; Machado FR; Cavalcanti AB;
Lancet; 2020 Oct; 396(10256):959-967. PubMed ID: 32896292
[TBL] [Abstract][Full Text] [Related]
18. Balanced evaluation of preliminary data on a candidate COVID-19 hydroxychloroquine treatment.
Seligmann H
Int J Antimicrob Agents; 2021 Mar; 57(3):106292. PubMed ID: 33714420
[No Abstract] [Full Text] [Related]
19. Use of combined treatment of 3rd-generation cephalosporin, azithromycin and antiviral agents on moderate SARs-CoV-2 patients in South Korea: A retrospective cohort study.
Hong W; Park YK; Kim BO; Park SK; Shin J; Jang SP; Park HW; Yang W; Jang J; Jang SW; Hwang TH
PLoS One; 2022; 17(5):e0267645. PubMed ID: 35507600
[TBL] [Abstract][Full Text] [Related]
20. Proactive Prophylaxis With Azithromycin and HydroxyChloroquine in Hospitalised Patients With COVID-19 (ProPAC-COVID): A structured summary of a study protocol for a randomised controlled trial.
Sivapalan P; Ulrik CS; Bojesen RD; Lapperre TS; Eklöf JV; Håkansson KEJ; Browatzki A; Tidemansen C; Wilcke JT; Janner J; Gottlieb V; Meteran H; Porsbjerg C; Madsen BL; Moberg M; Pedersen L; Benfield TL; Lundgren JD; Knop FK; Biering-Sørensen T; Ghanizada M; Sonne TP; Bødtger UCS; Jensen SG; Rasmussen DB; Brøndum E; Tupper OD; Sørensen SW; Alstrup G; Laursen CB; Møller UW; Sverrild A; Jensen JS
Trials; 2020 Jun; 21(1):513. PubMed ID: 32522282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
